Table 1.
Macrophage therapeutic targeting.
| Pathway | Target1 | Efficacy in Murine Models | Clinical Compounds | Clinical Trials in Solid Tumors2 |
|---|---|---|---|---|
| Recruitment | CD11b | Radiation, Chemotherapy | Rovelizumab | |
| CSF-1R | Single Agent (GBM, PDAC), Chemotherapy, Radiation, Angiogenesis Inhibitors | PLX3397, AMG820 IMC-CS4/LY3022855, RG7155/RO5509554 | NCT01596751 (O); NCT01444404 (C); NCT01349036 (O); NCT01004861 (O); NCT01346358 (O); NCT02265536 (O); NCT01494688 (O); NCT02323191 (O) | |
| CCL2 | Single Agent (metastasis, PDAC) | Carlumab | NCT00992186 (C); NCT01204996 (C) | |
| Neuropilin-1 | Angiogenesis inhibitors | MNRP1685A | NCT00747734 (C); NCT00954642 (C) | |
| ANG2 | Single Agent (mammary), Chemotherapy, Angiogenesis Inhibitors | Nesvacumab | NCT01271972 (O); NCT01688960 (O) | |
| Polarization | IL-4 | Single Agent (metastasis), Chemotherapy, Radiation | Pascolizumab | |
| IL4Rα | Dupilumab | |||
| IL-13 | Chemotherapy | Lebrikizumab, Tralokinumab, GSK679586, | ||
| FcγR | Chemotherapy | Rituximab (CD20), Ibrutinib (BTK), R788 (Syk) | ||
| Function | IL-6 | Clazakizumab, Olokizumab, Siltuximab, Sirukumab | NCT00433446 (C); NCT00385827 (C) NCT00841191 (C) | |
| IL-6R | Tocilizumab, Sarilumab | |||
| TNF-α | MAPK inhibitors | Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab | ||
| Activation | CD40 | Single Agent (PDAC), Chemotherapy | CP-870,893 | NCT00711191 (C); NCT01456585 (C) NCT02157831 (C); NCT01008527 (O) NCT02225002 (C); NCT00607048 (C) NCT01103635 (O) |
1
Only targets with clinical compounds are listed.
2
O: ongoing; C: completed. Data obtained from clinicaltrials.gov